Recombinant factor VIIa (NovoSeven®) as a hemostatic agent

Seminars in Hematology

Volumn 38, Issue 4 SUPPL. 12, 2001, Pages 43-47

  Hedner, Ulla ^a,b,c  

^a NOVO NORDISK A S   (Denmark)

^b Wallenblig Research Laboratory   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

BLEEDING; BOLUS INJECTION; CONFERENCE PAPER; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INJURY; MAJOR SURGERY; PRIORITY JOURNAL; THROMBIN TIME;

EID: 0035194439     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90147-7     Document Type: Conference Paper

References (45)

1. Effect of dextran on factor VIII (antihemophilic factor) and platelet function
2. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation
3. Recombinant factor VIIa for the treatment of congenital factor VII deficient patients
4. Thrombin, fibrin and platelets: A resonance loop in which von Willebrand factor is a necessary link
5. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin
6. RFVIIa corrects prothrombin time in cirrhotic patients: A preliminary study
7. NovoSeven in warfarin-treated patients
8. Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation
9. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma
10. Blood coagulation in hemophilia A and hemophilia C
11. Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa
12. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor
13. Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized ratios (INR) and prothrombin times induced by warfarin
14. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0
15. Successful use of recombinant factor VIIa (rFVIIa) for trauma-associated massive hemorrhage
16. Use of recombinant factor VIIa (NovoSeven) for dental extraction in a patient affected by platelet-type (pseudo) von Willebrand disease
17. Massive transfusion
18. Effect of rFVIIa on the permeability of fibrin gel
19. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
20. Haemostatic effect of factor VIIa in thrombocytopenic rabbits
21. Clinical use of recombinant FVIIa (rFVIIa)
22. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation
23. Use of recombinant factor VIIa in surgery in factor-VII-deficient patients
24. Efficacy and safety of rFVIIa in patients with severe coagulopathy undergoing laparoscopic liver biopsy
25. Treatment of traumatic bleeding with recombinant factor VIIa
26. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system
27. High-dose factor VIIa restores platelet activation and total thrombin generation in a model system mimicking hemophilia A or B conditions
28. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia
29. Recombinant factor VIIa for intractable surgical bleeding
30. Clinical experience with recombinant factor VIIa
31. Treatment of congenital factor VII deficiency with a new concentrate
32. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies
33. Determinants of substrate specificity for factor XIII
34. Platelet activity of high-dose factor VIIa is independent of tissue factor
35. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
36. Thrombin activates factor XI on activated platelets in the absence of factor XII
37. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa
38. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia
39. The tissue factor pathway: How it has become a "prima ballerina"
40. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis"
41. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII
42. Treatment of severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII
43. Structural studies of fibrinolysis by electron and light microscopy
44. Successful use of recombinant FVIIa (NovoSeven) in the management of intractable post-surgical intra-abdominal hemorrhage